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BACKGROUND AND PURPOSE 
High-mobility group box 1 (HMGB1), a nuclear protein, is actively or passively released 
during inflammation. Recombinant human soluble thrombomodulin (rhsTM), a medicine for 
treatment of disseminated intravascular coagulation (DIC), sequesters HMGB1 and promotes 
its degradation. Given evidence for involvement of HMGB1 in pain signaling, we determined 
if peripheral HMGB1 causes hyperalgesia, and then asked if rhsTM modulates the 
HMGB1-dependent hyperalgesia.  
EXPERIMENTAL APPROACH 
Mechanical nociceptive threshold and swelling in rat hindpaw were determined by the paw 
pressure test and by measuring paw thickness, respectively, and HMGB1 levels in rat hindpaw 
plantar tissue, dorsal root ganglion (DRG) and serum were determined by Western blotting or 
ELISA.  
KEY RESULTS 
Intraplantar (i.pl.) administration of HMGB1 rapidly evoked paw swelling and gradually 
caused hyperalgesia in rats. Systemic administration of rhsTM abolished HMGB1-induced 
hyperalgesia, and partially blocked paw swelling. Lipopolysaccharide (LPS), administered 
i.pl., rapidly produced mild paw swelling, and gradually caused hyperalgesia. The 
anti-HMGB1 neutralizing antibody abolished LPS-induced hyperalgesia, but partially 
inhibited paw swelling. rhsTM at a high dose, 10 mg kg
-1
, prevented both hyperalgesia and 
paw swelling caused by LPS. In contrast, rhsTM at low doses, 0.001-1 mg kg
-1
, abolished the 
LPS-induced hyperalgesia, but not paw swelling. HMGB1 levels greatly decreased in the 
hindpaw, but not DRG. Serum HMGB1 tended to increase after i.pl. LPS in rats pretreated 
with vehicle, but not rhsTM.  
CONCLUSION AND IMPLICATIONS 
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These data suggest that peripheral HMGB1 causes hyperalgesia, and that rhsTM abolishes 
HMGB1-dependent hyperalgesia, providing novel evidence for therapeutic usefulness of 




APC, activated protein C; DRG, dorsal root ganglion; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; HMGB1, high-mobility group box 1; LPS, lipopolysaccharide; RAGE, 
receptors for advanced glycation end products; rhsTM, recombinant human soluble 





Introduction        
 
High-mobility group box 1 (HMGB1) protein, a nuclear architectural chromatin-binding 
protein, is expressed by almost all mammalian cells, and released actively and/or passively 
from necrotic or damaged cells and activated macrophages during inflammation, playing 
pathological roles as one of damage-associated molecular patterns (DAMPs) (Scaffidi et al., 
2002; Harris and Raucci, 2006; Klune et al., 2008; Sims et al., 2010). HMGB1, once released 
into the extracellular space, is capable of binding to multiple cell surface receptors such as 
receptors for advanced glycation end products (RAGE) and toll-like receptor-4 (TLR4), 
facilitating inflammation and tissue damage (Wang et al., 1999; Schmidt et al., 2001; Scaffidi 
et al., 2002; Fiuza et al., 2003; Sunden-Cullberg et al., 2006). Accumulating evidence 
suggests the role of HMGB1 in pain processing. HMGB1 in the spinal cord and/or dorsal root 
ganglion (DRG) is upregulated in surgical neuropathic pain models induced by L5 spinal 
nerve ligation (Shibasaki et al., 2010) or by chronic constriction injury of the sciatic nerve 
(Kuang et al., 2012) and in a diabetic neuropathic pain model (Ren et al., 2012). Intrathecal 
administration of the neutralizing antibody against HMGB1 prevents or reverses the 
neuropathic pain/allodynia (Shibasaki et al., 2010; Ren et al., 2012) and bone cancer pain 
(Tong et al., 2010). Acute direct application of HMGB1 causes hyperexcitability of 
dissociated nociceptive DRG neurons isolated from rats (Feldman et al., 2012) and 
hypersensitivity of sciatic nerves to mechanical stimuli in rats (Chacur et al., 2001). 
Interestingly, thrombomodulin (TM), an endothelial anticoagulant cofactor (Esmon, 
2005), binds to HMGB1 and promotes its degradation by thrombin, leading to suppression of 
inflammation (Abeyama et al., 2005; Ito et al., 2008; Ito and Maruyama, 2011). TM is 
composed of five domains: the N-terminal lectin-like domain [thrombomodulin domain 
(TM-D) 1], epidermal growth factor (EGF)-like domain (TM-D2), O-glycosylation-rich 
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domain (TM-D3), C-terminal trans-membrane domain (TM-D4) and cytoplasmic domain 
(TM-D5). TM-D2 plays a critical role in the thrombin-catalyzed activation of protein C to 
activated protein C (APC), while TM-D1 binds to HMGB1 (Abeyama et al., 2005). 
Recombinant human soluble TM (rhsTM) that lacks TM-D4 and TM-D5 is approved for 
clinical treatment of disseminated intravascular coagulation (DIC) in Japan (Ito et al., 2011). 
Although rhsTM appears to exhibit anti-inflammatory activity in a manner dependent on 
TM-D1 and TM-D2 in humans, rhsTM is incapable of causing TM-D2-dependent production 
of protein C in mammals including rodents other than primates (Mohri et al., 1997). 
Nonetheless, rhsTM exhibits anti-inflammatory activity through TM-D1-dependent 
sequestration of HMGB1 (Abeyama et al., 2005) and promotion of its degradation in rodents 
(Ito et al., 2008; Ito et al., 2011). In this context, we hypothesize that rhsTM might modulate 
peripheral HMGM1-dependent facilitation of pain signals in rodents. 
In the present study, we thus tested if peripheral local injection of HMGB1 causes 
hyperalgesia in rats, and evaluated the effect of systemic administration of rhsTM on the 
peripheral HMGB1-dependent hyperalgesia. Here we provide evidence for the pronociceptive 
roles of HMGB1 in the peripheral tissue and novel therapeutic usefulness of rhsTM in 






Male Wistar rats (7-10 weeks old) were purchased from Kiwa Laboratory Animals Co., Ltd. 
(Wakayama, Japan). All animals were used with approval by Kinki University School of 
Pharmacy’s Committee for the Care and Use of Laboratory Animals, and all procedures were 
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in accordance with the Guiding Principles approved by The Japanese Pharmacological 
Society and with Use of Laboratory Animals published by the US National Institutes of 
Health. 
All studies involving animals are reported in accordance with the ARRIV guidelines for 
reporting experiments involving animals (Kilkenny et al., 2010; McGrath et al., 2010). 
 
Drugs and administration schedules 
 
Lipopolysaccharide (LPS) (Escherichia coli Serotype O26:B6) was purchased from 
Sigma-Aldrich Chemical (St Louis, MO). HMGB1 from bovine thymus, chicken 
anti-HMGB1 polyclonal antibody (neutralizing antibody) and chicken IgY were obtained 
from SHINO-TEST Corporation (Kanagawa, Japan). Recombinant human soluble 
thrombomodulin (rhsTM; thrombomodulin alfa) was provided by Asahi Kasei Pharma (Tokyo, 
Japan). LPS and HMGB1 were dissolved in saline, and rhsTM was in 0.002% Tween 
80-containing saline. The neutralizing antibody and chicken IgY were dissolved in 0.2 M PBS. 
Rats received intraplantar (i.pl.) administration of HMGB1 at 2, 10 or 20 μg per paw or LPS 
at 1 μg per paw in a volume of 0.1 ml. The HMGB1-neutralizing antibody or chicken IgY at 
50 or 100 μg per paw was coadministered i.pl. with LPS at 1 μg per paw in a volume of 0.1 
ml. rhsTM in a dose range of 0.001-10 mg kg
-1
 was administered i.p. to rats 30 min before i.pl. 
administration of HMGB1 or LPS, considering the previous reports (Abeyama et al., 2005; 
Shi et al., 2008).  
 
Measurement of mechanical and thermal nociception and of paw thickness 
 
Mechanical nociception was evaluated by the paw pressure test, using an analgesia meter 
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(MK-300, Muromachi Kikai Co., Tokyo, Japan); pressure was applied to the hindpaw of rats 
at a linearly increasing rate of 30 g s
-1
. The weight required to elicit nociceptive responses was 
determined as the nociceptive threshold, and a cut-off value of 500 g was used to avoid 
damage to the paw (Kawabata et al., 2007). In some experiments, the paw withdrawal latency 
to thermal stimuli was measured using a thermal analgesia meter (MK-330, Muromachi 
Kikai), as reported previously(Kawabata et al., 2001). The intensity of the thermal stimulus 
was adjusted to obtain baseline latencies of approximately 10 s (cut-off: 20s). Rats were used 
for experiments after training sessions for approximately 2 weeks. The baseline mechanical 
threshold, paw withdrawal latency to thermal stimuli and paw thickness were determined 
before and after drug administration, and are represented as the percentage of the baseline 
values (% baseline) and/or as the AUC (area under the curve) for the time course of the 
nociceptive threshold. The thickness of the hindpaw at the center was measured, as an 
indicator of oedema, using a tissue caliper with 0.05 mm accuracy.  
 
Determination of HMGB1 protein levels in the serum, hindpaw plantar tissue and DRG from 
rats 
 
Under anesthesia with i.p. administration of urethane at 1.5 g kg
-1
, the blood was collected 
from the abdominal aorta in the rats 1 h or 5 h after i.pl. LPS, and the ipsilateral DRG at 
L4-L6 levels and hindpaw plantar tissues (up to a level of the heel bone and metatarsal bones) 
were excised from the rats. Serum HMGB1 levels were determined using an enzyme-linked 
immunosorbent assay (ELISA) kit for HMGB1 (SHINO-TEST Corporation, Kanagawa, 
Japan). Tissue HMGB1 levels were assessed by Western blotting. Briefly, each sample was 
homogenized and sonicated in a RIPA buffer containing PBS, 1% Igepal Ca-630 





fluoride, 0.15 U ml
-1
 aprotinin and 1 mM sodium orthovanadate. After centrifugation, to the 
supernatant was added the same volume of 2x electrophoresis sample buffer containing 19% 
glycerol, 5.7% SDS, 240 mM Tris-HCl (pH 6.7). After addition of 2-mercaptoethanol and 
bromophenol blue, proteins in the samples were denatured at 95-100℃ for 5 min and 
separated by electrophoresis on 12.5 % SDS-polyacrylamide gels (Wako Pure Chem., Osaka, 
Japan) and transferred onto polyvinylidene difluoride membrane (Immobilon-P, Millipore 
corporation, Billerica, MA). The membrane was blocked with a blocking solution containing 
5% skim milk, 137 mM NaCl, 0.1% Tween 20 and 20 mM Tris-HCl (pH 7.6), and then 
incubated with the affinity-purified anti-HMGB1 rabbit polyclonal antibody (1:1000 dilution) 
(SHINO-TEST Corporation, Kanagawa, Japan) or the anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) rabbit polyclonal antibody (1:3000 dilution) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Immunopositive bands for HMGB1 and GAPDH 
around 29 and 37 kDa, respectively, were visualized by the enhanced chemiluminescence 
(ECL) detection reagent (Nacalai Tesque, Inc., Kyoto Japan). 
 
Determination of mRNA levels of HMGB1, RAGE and TLR4 in the hindpaw plantar tissue 
and DRG from rats 
 
The excised tissues were stabilized in an RNAlater reagent (Ambion, Austin, TX, USA). Total 
RNA was extracted from the homogenate of the bladder in the TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA). After the total RNA was reverse-transcribed, real-time PCR was 
performed using Light Cycler 480 (Roche Applied Sci., Basel, Switzerland). The volume of 
each reaction solution was 20 l, containing 10 l of 2× Power SYBR Green PCR Master 
Mix (Applied Biosystems Japan Ltd., Tokyo, Japan), 100 ng cDNA and 0.2 M each of 
forward and reverse primers. The cycling conditions of PCR were: preincubation at 50°C for 
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2 min followed by 95°C for 10 min, then 45 cycles of 95°C for15 s and 60°C for 60 s. The 
PCR primers employed for real-time PCR were: 5’-GTAATTTTCCGCGCTTTTGT-3’ 
(forward) and 5’-TCATCCAGGACTCATGTTCAGT-3’ (reverse) for rat HMGB1; 
5’-ACTACCGAGTCCGAGTCTACC-3’ (forward) and 
5’-GTAGCTCCCCTCAGACACACA-3’ (reverse) for rat RAGE; 
5’-CGGAAAGTTATTGTGGTGGTG-3’ (forward) and 
5’-GGACAATGAAGATGATGCCAG-3’ (reverse) for rat TLR4; 
5’-GATGGTGAAGGTCGGTGTGAAC-3’ (forward) and 
5’-TGACTGTGCCGTTGAACTTGC-3’ (reverse) for rat GAPDH. The product size was 114, 
116, 121, and 176 bp for HMGB1, RAGE, TLR4, and GAPDH, respectively. It is to be noted 
that TLR4 is defined in accordance with the nomenclature of the Guide to Receptors and 
Channels (Alexander et al., 2011). 
 
Morphological observation of the rat hindpaw tissue 
 
In some experiments, the hindpaw plantar tissue was fixed, embedded in paraffin, sectioned, 




Data are represented as means ± SEM. Statistical analyses were performed by Student’s t-test 
for two-group data and by Tukey’s test for multiple comparisons. Differences among 






Hyperalgesia induced by i.pl. administration of HMGB1 and its prevention by systemic 
administration of rhsTM in rats 
 
HMGB1, administered i.pl. at 10 and 20 μg per paw, but not 2 μg per paw, into the left 
hindpaw, gradually decreased the mechanical nociceptive threshold (Figure 1A). The paw 
thickness, an indicator of oedema, significantly increased and reached a plateau 1 h after i.pl. 
HMGB1 in the same dose range (Figure 1B). The paw withdrawal latency in response to 
thermal stimuli was shortened 5 h after i.pl. HMGB1 at 10-20 μg per paw (Fig. 1C). 
Histological signs of very mild inflammation characterized by infiltration of a few 
polynuclear leukocytes, but not typical oedema, were observed in the hindpaw 5 h after i.pl. 
administration of HMGB1 at 20 μg per paw (Figure. 1D). rhsTM, preadministered i.p. at 0.1 
mg kg
-1
, completely prevented the development of the HMGB1-induced mechanical 
hyperalgesia (Figure 1E). On the other hand, rhsTM at relatively higher doses, 0.1-1 mg kg
-1
, 
reduced the HMGB1-induced paw swelling (Figure 1F). rhsTM at 10 mg kg
-1
 altered neither 
mechanical nociceptive threshold nor paw thickness in naïve rats (n = 4-5, P > 0.05; not 
shown). 
 
The HMGB1-neutralizing antibody inhibits the hyperalgesia induced by i.pl. LPS in rats 
 
To clarify the role of endogenous HMGB1 in the development of inflammatory pain, we used 
a rat model for inflammatory hyperalgesia caused by LPS, known to trigger release of 
HMGB1 (Yanai et al., 2012). LPS, administered i.pl. at 1 μg per paw, caused some 
histological signs of mild inflammation characterized by slight oedema and polynuclear 
leukocyte infiltration (Figure 2A). The paw thickness, an indicator of oedema, rapidly 
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increased within 2 h after i.pl. LPS (Figure 2C), whereas the mechanical nociceptive threshold 
gradulally decreased, reaching a plateau around 4-5 h after i.pl. LPS (Figure 2B), in 
agreement with our previous study (Kawabata et al., 2007). Shortening of the paw withdrawal 
latency in response to thermal stimuli was also observed 5 h after i.pl. LPS (Figure 2D). The 
chicken anti-HMGB1 polyclonal antibody, a HMGB1-neutralizing antibody, when 
co-administered i.pl. at 50 and 100, but not 5, μg per paw with LPS, clearly prevented the 
development of the LPS-induced mechanical hyperalgesia (Figure 2B). The 
HMGB1-neutralizing antibody at 50 μg per paw failed to reduce the LPS-induced paw 
swelling, whereas a larger dose, 100 μg per paw, of the antibody significantly attenuated the 
paw swelling (Figure 2C). It was also confirmed that the LPS-induced thermal hyperalgesia 
was blocked by the HMGB1-neutralizing antibody (Figure 2D).  
 
Antihyperalgesic effect of rhsTM in rats treated with LPS 
 
Systemic (i.p.) preadministration of rhsTM at 10 mg kg
-1
, a relatively high dose, abolished the 
LPS-induced hyperalgesia (Figure 3A) and largely prevented the paw swelling in rats (Figure 
3B). In contrast, as did the HMGB1-neutralizing antibody (Figure 2B, C), rhsTM at 0.01-1 
mg kg
-1
, lower doses, almost completely inhibited the LPS-induced hyperalgesia, but not paw 
swelling (Figure 3C, D). Boiled rhsTM at 10 mg kg
-1
 unaffected the LPS-induced mechanical 
hyperalgesia (Figure 3E) or paw swelling (Figure 3F).  
 
Protein levels of HMGB1 in the hindpaw plantar tissue, DRG and serum of the rats after i.pl. 
LPS 
 
HMGB1 protein levels in the ipsilateral (left) hindpaw tissue significantly decreased 5 h, but 
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not 1 h, after i.pl. administration of LPS in the left hindpaw (Figure 4A, B). In DRG, HMGB1 
levels did not change by LPS treatment (Figure 4C). Preadministration of rhsTM did not 
prevent the LPS-induced decrease in the hindpaw HMGB1 levels (Figure 4B). Serum 
HMGB1 levels tended to increase 5 h after i.pl. administration of LPS in the rats treated with 
vehicle, but not rhsTM at 10 mg kg
-1
 (Figure 4E), while no change in serum HMGB1 levels 
was detected 1 h after i.pl. LPS (Figure 4D). rhsTM at 10 mg kg
-1
 itself did not affect 
HMGB1 levels in the hindpaw (Figure 4F), but significantly decreased serum HMGB1 levels 
(Figure 4G).   
 
mRNA levels for HMGB1, RAGE and TLR4 in the hindpaw plantar tissue and DRG after i.pl. 
LPS in the rats 
 
There was no significant change in mRNA levels for HMGB1, RAGE and TLR4 in the 
hindpaw or DRG 5 h after i.pl. administration of LPS in rats (Figure 5). 
 
Discussion and conclusions 
 
Our findings that a single i.pl. administration of HMGB1 caused mechanical and thermal 
hyperalgesia and that the HMGB1-neutralizing antibody abolished the LPS-induced 
hyperalgesia, suggest that peripheral HMGB1 plays a major role in nociceptor sensitization 
during inflammation. Further, our study demonstrates that rhsTM, known to sequester 
HMGB1 and promote its degradation, actually blocks the hyperalgesia caused by HMGB1 or 
LPS, implying novel therapeutic usefulness of rhsTM as an analgesic, in addition to a 
medicine for treatment of DIC.    
HMGB1, a nuclear, non-histone DNA-binding protein, is expressed in extensive cells 
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including neurons, and released actively or passively during inflammation (Kim et al., 2008; 
Klune et al., 2008). There is evidence for involvement of exogenous and endogenous 
HMGB1 in pain processing (Chacur et al., 2001; Tong et al., 2010; Feldman et al., 2012). In 
particular, HMGB1 present in the DRG and spinal cord appears to participate in the 
pathogenesis of neuropathic pain (Shibasaki et al., 2010; Kuang et al., 2012; Ren et al., 2012). 
Our present study provides novel evidence for involvement of exogenous and endogenous 
HMGB1 in the development of peripheral hyperalgesia. rhsTM sequesters HMGB1 
(Abeyama et al., 2005) and thereafter accelerates proteolytic degradation of HMGB1 by 
thrombin that takes 1-2 h in vitro (Ito et al., 2008). Therefore, our results that the development 
of paw swelling preceded the onset of hyperalgesia after i.pl. administration of HMGB1, 
might interpret why rhsTM exerted relatively minor inhibitory effect on the HMGB1-induced 
paw swelling, compared with its strong effect on the hyperalgesia (see Figure 1A, B). 
HMGB1 is considered to greatly participate in the LPS-induced hyperalgesia, but moderately 
contribute to the paw swelling, considering the extent of the effects of the 
HMGB1-neutralizing antibody (see Figure 2). This is in agreement with our results that 
rhsTM at relatively low doses prevented the development of the LPS-induced hyperalgesia, 
but not paw swelling (see Figure 3C, D). It is noteworthy that slight oedema, in addition to 
polynuclear leukocyte infiltration, was observed in the hindpaw tissues following i.pl. LPS, 
but not HMGB1 (see Figures 1D and 2A). The LPS-induced oedema or swelling in the 
hindpaw would thus appear to involve other pro-inflammatory mediators in addition to 
endogenous HMGB1. Nonetheless, rhsTM at 10 mg kg
-1
, a high dose, abolished both 
LPS-induced hyperalgesia and paw swelling (see Figure 3A, B). This might be explained by 
the previous evidence that TM also sequesters LPS through the TM-D1 at relatively high 
concentrations (Shi et al., 2008). The possibility cannot be ruled out that the different timing 
paradigm for administration of the anti-HMGB1 antibody and rhsTM that were 
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coadministered and preadministered, respectively, might affect the extent of their inhibitory 
effects on the paw swelling. 
Our data show that LPS treatment significantly and clearly decreased the protein levels of 
HMGB1 in the hindpaw plantar tissue, but not DRG, an effect resistant to rhsTM (see Figure 
4). It is now known that pro-inflammatory stimuli including LPS challenge cause active and 
passive release of HMGB1 from various tissues/cells (Taniguchi et al., 2003; Oyama et al., 
2010; Tsoyi et al., 2011; Nadatani et al., 2012; Wu et al., 2012), which might result in the 
decreased tissue HMGB1 levels, as shown in the present study. Although systemic LPS is 
known to increase serum HMGB1 levels (Lamkanfi et al., 2010; Yanai et al., 2012), i.pl. 
administration of LPS only slightly increased serum HMGB1 levels in rats treated with 
vehicle, but not rhsTM, in the present study. It is likely that a small amount of HMGB1 
released persistently from the hindpaw tissue in response to i.pl. administration of LPS might 
enter the blood stream and quickly disappear because of degradation by endothelial 
TM-thrombin complexes (Ito et al., 2008). In future studies, it would be necessary to detect 
extracellular HMGB1 released locally from the cells using a perfusion system.            
HMGB1 interacts with multiple cell surface receptors including RAGE and TLR4, a 
receptor for LPS (Wang et al., 1999; Schmidt et al., 2001; Scaffidi et al., 2002; Fiuza et al., 
2003; Sunden-Cullberg et al., 2006). RAGE is also expressed in neurons, modulates neuronal 
functions, and may be involved in diabetic neuropathy (Brett et al., 1993; Chou et al., 2004; 
Sugimoto et al., 2008). Our finding that the HMGB1-neutralizing antibody completely 
blocked the LPS-induced hyperalgesia, but exerted only partial inhibition of paw swelling 
(see Figure 2B, C, D), may suggest that endogenous HMGB1 causes hyperalgesia via 
activation of RAGE or other receptors distinct from TLR4, although neither RAGE nor TLR4 
was upregulated at mRNA levels (see Figure 5). What molecules HMGB1 targets for 
induction of hyperalgesia are still open to question. In the present study, the anti-HMGB1 
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neutralizing antibody was injected locally to the plantar region of the hindpaw, so that it 
would act locally within the paw tissues, considering the effective dose of the antibody that is 
not enough to be distributed at effective concentrations in the blood. However, the possibility 
cannot be ruled out that the anti-hyperalgesic effect of systemically administered rhsTM 
involves its actions on tissues/cells out of the paw tissue, including the brain and spinal cord, 
although rhsTM is not considered to easily penetrate into the CNS in consideration of its large 
molecular size. 
In conclusion, our data suggest that peripheral HMGB1 plays important roles in the 
development of inflammatory hyperalgesia and that rhsTM is available as a novel analgesic 
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Figure 1  Hyperalgesia induced by exogenously applied HMGB1 and its inhibition by 
systemic administration of rhsTM in rats. (A), (B) and (C) Time-courses of mechanical 
nociceptive threshold (A) and paw thickness (B) following i.pl. administration of HMGB1 at 
2, 10 or 20 µg per paw or vehicle, and the paw withdrawal latency in response to thermal 
stimuli 5 h after i.pl. HMGB1 in rats (C). Data show the mean with SEM for 4-5 rats. *P<0.05, 
**P<0.01 vs. Vehicle . (D) Histopathological appearance of the hindpaw tissue 5 h after i.pl. 
administration of vehicle (left) or HMGB1 at 20 µg per paw (right) in rats. The tissue was 
stained with hematoxylin-eosin. Arrows show slight infiltration of polynuclear leukocytes. 
Bars indicate 100 μm. (E) and (F) Mechanical nociceptive threshold (E) and paw thickness 
(F) after i.pl. administration of HMGB1 in rats treated with rhsTM. rhsTM at 0.1 or 1 mg kg
-1
 
or vehicle was administered i.p. 30 min before i.pl. administration of HMGB1 at 10 µg per 
paw or vehicle. Data show the mean with SEM for 5-11 rats. *P<0.05, **P<0.01 vs. Vehicle + 
Vehicle; †P<0.05, ††P<0.01 vs. Vehicle + HMGB1.  
 
Figure 2  Inflammatory hyperalgesia induced by LPS and its inhibition by the 
HMGB1-neutralizing antibody in rats. (A) Histopathological appearance of the hindpaw 
tissue 5 h after i.pl. administration of vehicle (left) or LPS at 1 μg per paw (right) in rats. The 
tissue was stained with hematoxylin-eosin. Arrows and arrow heads show slight infiltration of 
polynuclear leukocytes and oedematous lesion, respectively. Bars indicate 100 μm. (B), (C) 
and (D) Mechanical nociceptive threshold (B), paw thickness (C) and paw withdrawal latency 
in response to thermal stimuli (D) after i.pl. combined administration of LPS and IgY or the 
HMGB1-neutralizing antibody in rats. Chicken anti-HMGB1 polyclonal antibody 
(neutralizing antibody) at 5, 50 or 100 μg per paw or chicken IgY at 50 μg per paw was 
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co-administered i.pl. with LPS at 1 μg per paw. AUC3-5 was calculated from the 
time-threshold curve between 3 and 5 h after i.pl. LPS (B, right), and the latency was 
determined 5 h i.pl. LPS (D). V, vehicle. Data show the mean with SEM for 4-10 rats. 
*P<0.05, **P<0.01 vs. Vehicle; †P<0.05, ††P<0.01 vs. IgY / LPS. 
 
Figure 3  Effect of rhsTM on LPS-induced inflammatory hyperalgesia in rats. (A) and (B) A 
high dose of rhsTM abolishes both LPS-induced mechanical hyperalgesia (A) and paw 
swelling (B). rhsTM at 10 mg kg
-1
 or vehicle was administered i.p. 30 min before i.pl. 
administration of LPS at 1 μg per paw or vehicle. (C) and (D) Low doses of rhsTM prevent 
the LPS-induced hyperalgesia (C), but not paw swelling (D), in rats. rhsTM at 0.001-1 mg 
kg
-1
 or vehicle was administered i.p. 30 min before i.pl. administration of LPS at 1 μg per paw 
or vehicle. (E) and (F) Lack of effect of boiled rhsTM (bTM) on LPS-induced hyperalgesia 
(E) or paw swelling (F) in rats. bTM was prepared by boiling rhsTM for 10 min, and 
administered i.p. at 10 mg kg
-1
, 30 min before i.pl. LPS. AUC3-5 was calculated from the 
time-threshold curve between 3 and 5 h after i.pl. LPS (C, E), and paw swelling was evaluated 
by measuring paw thickness 5 h after i.pl. LPS (D, F). V, vehicle. Data show the mean with 
SEM for 8-12 (A and B) or 4-9 (C, D, E and F) rats. *P<0.05, **P<0.01 vs. Vehicle + Vehicle; 
†P<0.05, ††P<0.01 vs. Vehicle + LPS. 
 
Figure 4  HMGB1 protein levels in the hindpaw, DRG and serum after i.pl. administration 
of LPS in rats. rhsTM at 10 mg kg
-1
 or vehicle was administered i.p. 30 min before i.pl. 
administration of LPS at 1 µg per paw. (A), (B) and (C) Expression of HMGB1 protein in the 
hindpaw plantar tissue 1 h (A) and 5 h (B) after i.pl. LPS, and in DRG at L4-L6 levels (C) 5 h 
after i.pl. LPS. The rats pretreated with rhsTM or not received i.pl. administration of LPS the 
left hindpaw, and HMGB1 levels in the left (L) and/or right (R) hindpaws (A, B) and in the 
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left DRG (C) were assessed by Western blotting. (D) and (E) Serum HMGB1 levels 1 h (D) 
and 5 h (E) after i.pl. LPS in rats, as assessed by ELISA. (F) and (G) HMGB1 levels in the 
hindpaw (F) and serum (G) 5 h after i.p. administration of rhsTM at 10 mg kg
-1
 or vehicle in 
naïve rats. Photographs show typical examples of Western blotting for HMGB1 and GAPDH. 
Levels of each protein are quantified by densitometry in Western blotting. Data show the 
mean with SEM for 4 (A, B, C, D, F, G) or 5-8 (E) rats. *P<0.05 vs. Vehicle + Vehicle, or 
Vehicle. 
 
Figure 5  Levels of mRNA for HMGB1, RAGE and TLR4 in the hindpaw and DRG after 
i.pl. administration of LPS in the rats. The ipsilateral hindpaw and DRG at L4-L6 levels were 
collected 5 h after i.pl. administration of LPS at 1 µg per paw in rats, and mRNAs were 
reverse-transcribed and quantified by the real-time PCR method. Data show the mean with 
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